JP2007530528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530528A5 JP2007530528A5 JP2007504503A JP2007504503A JP2007530528A5 JP 2007530528 A5 JP2007530528 A5 JP 2007530528A5 JP 2007504503 A JP2007504503 A JP 2007504503A JP 2007504503 A JP2007504503 A JP 2007504503A JP 2007530528 A5 JP2007530528 A5 JP 2007530528A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- spt
- pharmaceutical composition
- mammal
- serine palmitoyltransferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000015785 Serine C-Palmitoyltransferase Human genes 0.000 claims 22
- 108010024814 Serine C-palmitoyltransferase Proteins 0.000 claims 22
- 239000003112 inhibitor Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 229940122498 Gene expression inhibitor Drugs 0.000 claims 2
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 claims 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 2
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 125000003553 myriocin group Chemical group 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims 1
- 108010000775 Hydroxymethylglutaryl-CoA synthase Proteins 0.000 claims 1
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 claims 1
- YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- -1 fibrate Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical group COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims 1
- 229950004514 torcetrapib Drugs 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55702104P | 2004-03-26 | 2004-03-26 | |
| PCT/IB2005/000733 WO2005092325A1 (en) | 2004-03-26 | 2005-03-21 | Use of a serine palmitoyltransferase (spt) inhibitor to treat atherosclerosis and dyslipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007530528A JP2007530528A (ja) | 2007-11-01 |
| JP2007530528A5 true JP2007530528A5 (https=) | 2008-05-08 |
Family
ID=34961685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504503A Withdrawn JP2007530528A (ja) | 2004-03-26 | 2005-03-21 | アテローム性動脈硬化症および脂質代謝異常の治療を目的としたセリンパルミトイルトランスフェラーゼ（ｓｐｔ）阻害剤の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080027088A1 (https=) |
| EP (1) | EP1732538A1 (https=) |
| JP (1) | JP2007530528A (https=) |
| BR (1) | BRPI0507998A (https=) |
| CA (1) | CA2560920A1 (https=) |
| WO (1) | WO2005092325A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016657A1 (ja) * | 2004-08-11 | 2006-02-16 | Chugai Seiyaku Kabushiki Kaisha | Hcv感染症を治療または予防するための薬剤 |
| EP1923060A1 (en) * | 2006-11-08 | 2008-05-21 | Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO | Combinations of a sphingolipid and an HMG-CoA reductase inhibitor for treating hypercholesterolemia |
| US20090264528A1 (en) * | 2008-04-18 | 2009-10-22 | The Research Foundation Of State University Of New York | Serine palmitoylcoa transferase (spt) inhibition by myriocin or genetic deficiency decreases cholesterol absorption |
| US20090264514A1 (en) * | 2008-04-18 | 2009-10-22 | The Research Foundation Of State University Of New York | SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY |
| TW201010692A (en) * | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
| WO2010061881A1 (ja) | 2008-11-26 | 2010-06-03 | 中外製薬株式会社 | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| ITMI20090284A1 (it) * | 2009-02-26 | 2010-08-27 | Consiglio Nazionale Ricerche | Uso di inibitori della serina palmitoiltrasferasi per la prevenzione e il rallentamento delle degenerazioni retiniche ereditarie e relative composizioni |
| EP2526426A1 (en) * | 2010-01-20 | 2012-11-28 | Universität Zürich | Method for assaying diseases characterised by dyslipidemia |
| EP2538939A1 (en) * | 2010-02-24 | 2013-01-02 | Universität Zürich | Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids |
| CN103154742B (zh) | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| KR101384349B1 (ko) | 2010-12-30 | 2014-04-24 | 충북대학교 산학협력단 | 세린-팔미토일트랜스퍼라아제 활성 저해제를 유효성분으로 포함하는 항암용 조성물 |
| AU2012340563B2 (en) | 2011-11-21 | 2017-01-19 | The Institute For Ethnomedicine | L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190894B1 (en) * | 1993-03-19 | 2001-02-20 | The Regents Of The University Of California | Method and compositions for disrupting the epithelial barrier function |
| US5989803A (en) * | 1997-09-05 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase |
| WO2002048325A2 (en) * | 2000-12-15 | 2002-06-20 | Bayer Aktiengesellschaft | Regulation of human serine palmitoyltransferase |
-
2005
- 2005-03-21 BR BRPI0507998-5A patent/BRPI0507998A/pt not_active IP Right Cessation
- 2005-03-21 CA CA002560920A patent/CA2560920A1/en not_active Abandoned
- 2005-03-21 EP EP05708781A patent/EP1732538A1/en not_active Withdrawn
- 2005-03-21 WO PCT/IB2005/000733 patent/WO2005092325A1/en not_active Ceased
- 2005-03-21 US US10/594,348 patent/US20080027088A1/en not_active Abandoned
- 2005-03-21 JP JP2007504503A patent/JP2007530528A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022116083A5 (https=) | ||
| HRP20241674T1 (hr) | 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe | |
| JP2007530528A5 (https=) | ||
| Shitara et al. | Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions | |
| HRP20120818T1 (hr) | Metoda za lijeäśenje ateroskleroze, dislipidemija i srodnih stanja | |
| EP3383378B1 (en) | Methods for inhibiting conversion of choline to trimethylamine (tma) | |
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| JP2010047616A5 (https=) | ||
| WO2005062824A8 (en) | Anti-hypercholesterolemic compounds | |
| JP2007277267A5 (https=) | ||
| AR081032A1 (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| RU2006102981A (ru) | Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы | |
| WO2006138163A3 (en) | Anti-hypercholesterolemic compounds | |
| JP2015524439A5 (https=) | ||
| NO20082075L (no) | Anti-hyperkolesterolemiske forbindelser | |
| WO2006135480A3 (en) | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts | |
| JP2006514611A5 (https=) | ||
| Oliveira et al. | HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015) | |
| JP2006512361A5 (https=) | ||
| JP2007527433A5 (https=) | ||
| JP2010519290A (ja) | 心血管系障害の治療のための併用療法、組成物及び方法 | |
| Paraskevas et al. | Pleiotropic effects of statins: implications for a wide range of diseases | |
| Yoshitomi et al. | Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study | |
| JP2008513379A5 (https=) | ||
| JP2003524582A5 (https=) |